Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher P Evans

Showing results (141-150 of 208) with videos related to

Pageof 21
Sort By:
European Urology Focus|July 21, 2017
Targeting Adaptive Pathways in Metastatic Treatment-Resistant Prostate Cancer: Update on the Stand Up 2 Cancer/Prostate Cancer Foundation-Supported West Coast Prostate Cancer Dream TeamRahul Aggarwal, Tomasz M Beer, Martin Gleave, et al.
Iscience|February 8, 2024
IGFBP3 promotes resistance to Olaparib via modulating EGFR signaling in advanced prostate cancerAmy R Leslie, Shu Ning, Cameron M Armstrong, et al.
European Urology|February 8, 2011
MicroRNA in prostate, bladder, and kidney cancer: a systematic reviewJames W F Catto, Antonio Alcaraz, Anders S Bjartell, et al.
European Journal of Cancer (Oxford, England : 1990)|November 22, 2025
Enzalutamide with or without leuprolide in patients with high-risk biochemically recurrent prostate cancer: EMBARK post hoc analysis by ageNeal D Shore, Ugo De Giorgi, Matko Kalac, et al.
Cancer Research|April 3, 2008
Regulation of Id1 expression by SRC: implications for targeting of the bone morphogenetic protein pathway in cancerOliver Gautschi, Clifford G Tepper, Phillip R Purnell, et al.
Molecular Cancer Therapeutics|January 28, 2022
Olaparib-Induced Senescence Is Bypassed through G2-M Checkpoint Override in Olaparib-Resistant Prostate CancerAlan P Lombard, Cameron M Armstrong, Leandro S D'Abronzo, et al.
Molecular Cancer Therapeutics|August 5, 2022
Bioengineered BERA-Wnt5a siRNA Targeting Wnt5a/FZD2 Signaling Suppresses Advanced Prostate Cancer Tumor Growth and Enhances Enzalutamide TreatmentShu Ning, Chengfei Liu, Wei Lou, et al.
Cancer Research|November 18, 2015
miR-124 and Androgen Receptor Signaling Inhibitors Repress Prostate Cancer Growth by Downregulating Androgen Receptor Splice Variants, EZH2, and SrcXu-Bao Shi, Ai-Hong Ma, Lingru Xue, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 15, 2020
Steroid Sulfatase Stimulates Intracrine Androgen Synthesis and is a Therapeutic Target for Advanced Prostate CancerCameron M Armstrong, Chengfei Liu, Liangren Liu, et al.
European Urology Oncology|July 9, 2023
The Impact of Positron Emission Tomography Imaging and Tumor Molecular Profiling on Risk Stratification, Treatment Choice, and Oncological Outcomes of Patients with Primary or Relapsed Prostate Cancer: An International Collaborative Review of the Existing LiteratureAkshay Sood, Amar U Kishan, Christopher P Evans, et al.
Pageof 21

Showing results (141-150 of 208) with videos related to

Sort By:
Pageof 21
European Urology Focus|July 21, 2017
Targeting Adaptive Pathways in Metastatic Treatment-Resistant Prostate Cancer: Update on the Stand Up 2 Cancer/Prostate Cancer Foundation-Supported West Coast Prostate Cancer Dream TeamRahul Aggarwal, Tomasz M Beer, Martin Gleave, et al.
Iscience|February 8, 2024
IGFBP3 promotes resistance to Olaparib via modulating EGFR signaling in advanced prostate cancerAmy R Leslie, Shu Ning, Cameron M Armstrong, et al.
European Urology|February 8, 2011
MicroRNA in prostate, bladder, and kidney cancer: a systematic reviewJames W F Catto, Antonio Alcaraz, Anders S Bjartell, et al.
European Journal of Cancer (Oxford, England : 1990)|November 22, 2025
Enzalutamide with or without leuprolide in patients with high-risk biochemically recurrent prostate cancer: EMBARK post hoc analysis by ageNeal D Shore, Ugo De Giorgi, Matko Kalac, et al.
Cancer Research|April 3, 2008
Regulation of Id1 expression by SRC: implications for targeting of the bone morphogenetic protein pathway in cancerOliver Gautschi, Clifford G Tepper, Phillip R Purnell, et al.
Molecular Cancer Therapeutics|January 28, 2022
Olaparib-Induced Senescence Is Bypassed through G2-M Checkpoint Override in Olaparib-Resistant Prostate CancerAlan P Lombard, Cameron M Armstrong, Leandro S D'Abronzo, et al.
Molecular Cancer Therapeutics|August 5, 2022
Bioengineered BERA-Wnt5a siRNA Targeting Wnt5a/FZD2 Signaling Suppresses Advanced Prostate Cancer Tumor Growth and Enhances Enzalutamide TreatmentShu Ning, Chengfei Liu, Wei Lou, et al.
Cancer Research|November 18, 2015
miR-124 and Androgen Receptor Signaling Inhibitors Repress Prostate Cancer Growth by Downregulating Androgen Receptor Splice Variants, EZH2, and SrcXu-Bao Shi, Ai-Hong Ma, Lingru Xue, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 15, 2020
Steroid Sulfatase Stimulates Intracrine Androgen Synthesis and is a Therapeutic Target for Advanced Prostate CancerCameron M Armstrong, Chengfei Liu, Liangren Liu, et al.
European Urology Oncology|July 9, 2023
The Impact of Positron Emission Tomography Imaging and Tumor Molecular Profiling on Risk Stratification, Treatment Choice, and Oncological Outcomes of Patients with Primary or Relapsed Prostate Cancer: An International Collaborative Review of the Existing LiteratureAkshay Sood, Amar U Kishan, Christopher P Evans, et al.
Pageof 21